No significant associations seen for age, vaccine booster type, history of breast cancer with time to resolution
Adverse Reactions to BNT162b2 Mild, Moderate for 5- to 11-Year-Olds
Based on data from three U.S. safety monitoring systems, adverse events were mild-to-moderate, and myocarditis occurred rarely
Veterans Report Low Rates of Adverse Events With mRNA Vaccines
Rates slightly higher at 42 days for those receiving Pfizer versus Moderna
One in Nine May Get Delayed Large Local Reaction After Moderna Vaccine
Higher risk seen among women and among individuals aged 30 to 69 years
Risk for Guillain-Barré Syndrome Up After Ad.26.COV2.S Vaccination
Adjusted rate ratio of 20.56 found in head-to-head comparison of Ad.26.COV2.S with mRNA COVID-19 vaccines
Drug Interaction Checkers Could Have Caught Adverse Events
More than three-quarters of COVID-19-associated drug-drug interactions could have been identified
Survivors of Severe COVID-19 Report Many Long-Term Symptoms
Findings show physical, mental, and cognitive symptoms one year after ICU stay for COVID-19
Thrombosis, Thrombocytopenia Syndrome Up After Ad26.COV2.S
Reporting rates 3.83 per million vaccine doses for Ad26.COV2.S versus 0.00855 per million for mRNA-based vaccines
Serious Adverse Effects From COVID-19 Vaccines Reported Rarely
Full vaccination dose, younger age, female sex, and previously having had COVID-19 linked to greater odds of adverse effects
Adverse Events Rare After BNT162b2 Vaccine in 5- to 11-Year-Olds
Data show 4,249 reports of adverse events after about 8.7 million doses of vaccine were administered; 97.6 percent not serious